Immatics Operating Margin

IMTX Stock  USD 7.84  0.03  0.38%   
Immatics NV fundamentals help investors to digest information that contributes to Immatics' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Immatics Operating Margin Analysis

Immatics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Operating Margin 
 = 
Operating Income 
Revenue 
X
100 
More About Operating Margin | All Equity Analysis

Current Immatics Operating Margin

    
  0.09 %  
Most of Immatics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immatics NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Compare to competition

Based on the recorded statements, Immatics NV has an Operating Margin of 0.0918%. This is 100.26% lower than that of the Healthcare sector and 100.08% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 101.67% lower than that of the firm.

Immatics Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics could also be used in its relative valuation, which is a method of valuing Immatics by comparing valuation metrics of similar companies.
Immatics is currently under evaluation in operating margin category among related companies.

Immatics Fundamentals

About Immatics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immatics NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immatics NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 388 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immatics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immatics' short interest history, or implied volatility extrapolated from Immatics options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immatics Piotroski F Score and Immatics Altman Z Score analysis. You can also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
625.1 M
Quarterly Revenue Growth
1.337
Return On Assets
0.0313
Return On Equity
0.4583
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.